{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:43:21Z","timestamp":1779155001454,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"MDM Spa Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40520-019-01229-z","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T08:02:32Z","timestamp":1559203352000},"page":"449-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial\u2014the CONIVaD trial"],"prefix":"10.1007","volume":"32","author":[{"given":"Emilia","family":"Salvadori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Poggesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Donnini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Rinnoci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Squitieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Tudisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Fierini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Melone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Pescini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-8530","authenticated-orcid":false,"given":"Leonardo","family":"Pantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1474-4422(03)00305-3","volume":"2","author":"JT O\u2019Brien","year":"2003","unstructured":"O\u2019Brien JT, Erkinjuntti T, Reisberg B et al (2003) Vascular cognitive impairment. Lancet Neurol 2:89\u201398","journal-title":"Lancet Neurol"},{"key":"1229_CR2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(10)70104-6","volume":"9","author":"L Pantoni","year":"2010","unstructured":"Pantoni L (2010) Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9:689\u2013701","journal-title":"Lancet Neurol"},{"key":"1229_CR3","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1474-4422(13)70124-8","volume":"12","author":"JM Wardlaw","year":"2013","unstructured":"Wardlaw JM, Smith EE, Biessels GJ et al (2013) Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12:822\u2013838","journal-title":"Lancet Neurol"},{"key":"1229_CR4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2004.09.014","volume":"226","author":"L Pantoni","year":"2004","unstructured":"Pantoni L (2004) Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. J Neurol Sci 226:67\u201370","journal-title":"J Neurol Sci"},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.117.005568","volume":"1","author":"EE Smith","year":"2017","unstructured":"Smith EE, Cieslak A, Barber P et al (2017) Therapeutic strategies and drug development for vascular cognitive impairment. J Am Heart Assoc 1:1. \nhttps:\/\/doi.org\/10.1161\/JAHA.117.005568","journal-title":"J Am Heart Assoc"},{"key":"1229_CR6","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/brain\/121.12.2249","volume":"121","author":"NR Selden","year":"1998","unstructured":"Selden NR, Gitelman DR, Salamon-Murayama N, Parrish TB, Mesulam MM (1998) Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121:2249\u20132257","journal-title":"Brain"},{"key":"1229_CR7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/01.WNL.0000078943.50032.FC","volume":"61","author":"D Wilkinson","year":"2003","unstructured":"Wilkinson D, Doody R, Helme R et al (2003) Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61:479\u2013486","journal-title":"Neurology"},{"key":"1229_CR8","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.STR.0000091396.95360.E1","volume":"34","author":"S Black","year":"2003","unstructured":"Black S, Rom\u00e1n GC, Geldmacher DS et al (2003) Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 34:2323\u20132330","journal-title":"Stroke"},{"key":"1229_CR9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1474-4422(08)70046-2","volume":"7","author":"M Dichgans","year":"2008","unstructured":"Dichgans M, Markus HS, Salloway S et al (2008) Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 7:310\u2013318","journal-title":"Lancet Neurol"},{"key":"1229_CR10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0140-6736(02)08267-3","volume":"359","author":"T Erkinjuntti","year":"2002","unstructured":"Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV (2002) Efficacy of galantamine in probable vascular dementia and Alzheimer\u2019s disease combined with cerebrovascular disease: a randomized trial. Lancet 359:1283\u20131290","journal-title":"Lancet"},{"key":"1229_CR11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/01.wnl.0000266625.31615.f6","volume":"69","author":"AP Auchus","year":"2007","unstructured":"Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C (2007) Galantamine treatment of vascular dementia: a randomized trial. Neurology 69:448\u2013458","journal-title":"Neurology"},{"key":"1229_CR12","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1185\/03007990802328142","volume":"24","author":"C Ballard","year":"2008","unstructured":"Ballard C, Sauter M, Scheltens P et al (2008) Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin 24:2561\u20132574","journal-title":"Curr Med Res Opin"},{"key":"1229_CR13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0404.2009.01263.x","volume":"121","author":"K Narasimhalu","year":"2010","unstructured":"Narasimhalu K, Effendy S, Sim CH et al (2010) A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurol Scand 121:217\u2013224","journal-title":"Acta Neurol Scand"},{"key":"1229_CR14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1161\/01.STR.0000020094.08790.49","volume":"33","author":"JM Orgogozo","year":"2002","unstructured":"Orgogozo JM, Rigaud AS, St\u00f6ffler A, M\u00f6bius HJ, Forette F (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 33:1834\u20131839","journal-title":"Stroke"},{"key":"1229_CR15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00004850-200211000-00005","volume":"17","author":"G Wilcock","year":"2002","unstructured":"Wilcock G, M\u00f6bius HJ, St\u00f6ffler A, MMM 500 group, (2002) A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 17:297\u2013305","journal-title":"Int Clin Psychopharmacol"},{"key":"1229_CR16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(07)70195-3","volume":"6","author":"H Kavirajan","year":"2007","unstructured":"Kavirajan H, Schneider LS (2007) Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 6:782\u2013792","journal-title":"Lancet Neurol"},{"key":"1229_CR17","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","volume":"42","author":"PB Gorelick","year":"2011","unstructured":"Gorelick PB, Scuteri A, Black SE et al (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 42:2672\u20132713","journal-title":"Stroke"},{"key":"1229_CR18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0024-3205(79)90269-8","volume":"25","author":"L Wecker","year":"1979","unstructured":"Wecker L, Schmidt DE (1979) Central cholinergic function in the rat relationship to choline administration. Life Sci 25:375\u2013384","journal-title":"Life Sci"},{"key":"1229_CR19","first-page":"1","volume":"63","author":"JJ Secades","year":"2016","unstructured":"Secades JJ (2016) Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol 63:1\u201373","journal-title":"Rev Neurol"},{"key":"1229_CR20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000346602","volume":"35","author":"J Alvarez-Sab\u00edn","year":"2013","unstructured":"Alvarez-Sab\u00edn J, Ortega G, Jacas C et al (2013) Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc Dis 35:146\u2013154","journal-title":"Cerebrovasc Dis"},{"key":"1229_CR21","first-page":"CD000269","volume":"2","author":"M Fioravanti","year":"2005","unstructured":"Fioravanti M, Yanagi M (2005) Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2:CD000269","journal-title":"Cochrane Database Syst Rev"},{"key":"1229_CR22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/030006059101900406","volume":"19","author":"R Di Perri","year":"1991","unstructured":"Di Perri R, Coppola G, Ambrosio LA, Grasso A, Puca FM, Rizzo M (1991) A multicentre trial to evaluate the efficacy and tolerability of \u03b1-glycerylphosphoryl-choline versus cytidine diphosphocholine in patients with vascular dementia. J Int Med Res 19:330\u2013341","journal-title":"J Int Med Res"},{"key":"1229_CR23","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0011-393X(05)80518-1","volume":"52","author":"A Muratorio","year":"1992","unstructured":"Muratorio A, Bonuccelli U, Nuti A, Battistini N, Passero S (1992) A neurotropic approach to the treatment of multi-infarct dementia using L-\u03b1-glyceryl-phoshorylcholine. Curr Ther Res 52:741\u2013751","journal-title":"Curr Ther Res"},{"key":"1229_CR24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00002826-199619060-00003","volume":"19","author":"L Pantoni","year":"1996","unstructured":"Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D (1996) A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 19:497\u2013506","journal-title":"Clin Neuropharmacol"},{"key":"1229_CR25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0022-510X(00)00301-4","volume":"175","author":"L Pantoni","year":"2000","unstructured":"Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T (2000) The scandinavian multi-infarct dementia trial: a double blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci 175:116\u2013123","journal-title":"J Neurol Sci"},{"key":"1229_CR26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0022-510X(00)00300-2","volume":"175","author":"L Pantoni","year":"2000","unstructured":"Pantoni L, Rossi R, Inzitari D et al (2000) Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the scandinavian multi-infarct dementia trial. J Neurol Sci 175:124\u2013134","journal-title":"J Neurol Sci"},{"key":"1229_CR27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/01.STR.0000155686.73908.3e","volume":"36","author":"L Pantoni","year":"2005","unstructured":"Pantoni L, del Ser T, Soglian AG et al (2005) Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 36:619\u2013624","journal-title":"Stroke"},{"key":"1229_CR28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0197-4580(00)00225-6","volume":"22","author":"E Farkas","year":"2001","unstructured":"Farkas E, De Jong GI, Apr\u00f3 E, Keuker JI, Luiten PG (2001) Calcium antagonists decrease capillary wall damage in aging hypertensive rat brain. Neurobiol Aging 22:299\u2013309","journal-title":"Neurobiol Aging"},{"key":"1229_CR29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0047-6374(92)90083-P","volume":"64","author":"GI de Jong","year":"1992","unstructured":"de Jong GI, Traber J, Luiten PG (1992) Formation of cerebrovascular anomalies in the ageing rat is delayed by chronic nimodipine application. Mech Ageing Dev 64:255\u2013272","journal-title":"Mech Ageing Dev"},{"key":"1229_CR30","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/01616412.2017.1356157","volume":"39","author":"M Hu","year":"2017","unstructured":"Hu M, Liu Z, Lv P et al (2017) Nimodipine activates neuroprotective signaling events and inactivates autophages in the VCID rat hippocampus. Neurol Res 39:904\u2013909","journal-title":"Neurol Res"},{"key":"1229_CR31","first-page":"CD000147","volume":"3","author":"JM L\u00f3pez-Arrieta","year":"2002","unstructured":"L\u00f3pez-Arrieta JM, Birks J (2002) Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 3:CD000147","journal-title":"Cochrane Database Syst Rev"},{"key":"1229_CR32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1749-6632.2000.tb06376.x","volume":"903","author":"T Erkinjuntti","year":"2000","unstructured":"Erkinjuntti T, Inzitari D, Pantoni L et al (2000) Limitations of clinical criteria for the diagnosis of vascular dementia in clinical trials. Is a focus on subcortical vascular dementia a solution? Ann N Y Acad Sci 903:262\u2013272","journal-title":"Ann N Y Acad Sci"},{"key":"1229_CR33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JAD-141569","volume":"42","author":"A Poggesi","year":"2014","unstructured":"Poggesi A, Salvadori E, Valenti R et al (2014) The Florence VAS-COG clinic: a model for the care of patients with cognitive and behavioral disturbances consequent to cerebrovascular diseases. J Alzheimers Dis 42:453\u2013461","journal-title":"J Alzheimers Dis"},{"key":"1229_CR34","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412\u20132414","journal-title":"Neurology"},{"key":"1229_CR35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000081050","volume":"24","author":"L Pantoni","year":"2005","unstructured":"Pantoni L, Basile AM, Pracucci G et al (2005) Impact of age-related cerebral white matter changes on the transition to disability\u2014the LADIS study: rationale, design and methodology. Neuroepidemiology 24:51\u201362","journal-title":"Neuroepidemiology"},{"key":"1229_CR36","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/jnnp.53.12.1080","volume":"53","author":"JC Van Swieten","year":"1990","unstructured":"Van Swieten JC, Hijdra A, Koudstaal PJ, Van Gijn J (1990) Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry 53:1080\u20131083","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1229_CR37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad B, Palmer K, Kivipelto M et al (2004) Mild cognitive impairment\u2014beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. J Intern Med 256:240\u2013246","journal-title":"J Intern Med"},{"key":"1229_CR38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7:263\u2013269","journal-title":"Alzheimers Dement"},{"key":"1229_CR39","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Arlington","edition":"5"},{"key":"1229_CR40","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","volume":"185","author":"S Katz","year":"1963","unstructured":"Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 185:914\u2013919","journal-title":"JAMA"},{"key":"1229_CR41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179\u2013186","journal-title":"Gerontologist"},{"key":"1229_CR42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5014\/ajot.53.5.471","volume":"53","author":"I Gelinas","year":"1999","unstructured":"Gelinas I, Gauthier L, McIntire M, Gauthier S (1999) Development of a functional measure for persons with Alzheimer\u2019s disease: the disability assessment for dementia. Am J Occup Ther 53:471\u2013483","journal-title":"Am J Occup Ther"},{"key":"1229_CR43","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.STR.28.11.2155","volume":"28","author":"A van Straten","year":"1997","unstructured":"van Straten A, de Haan RJ, Limburg M, Schuling J, Bossuyt PM, van den Bos GA (1997) A stroke-adapted 30-item version of the sickness impact profile to assess quality of life (SA-SIP30). Stroke 28:2155\u20132161","journal-title":"Stroke"},{"key":"1229_CR44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/014662167700100306","volume":"1","author":"LS Radloff","year":"1977","unstructured":"Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385\u2013401","journal-title":"Appl Psychol Meas"},{"key":"1229_CR45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1176\/jnp.12.2.233","volume":"12","author":"D Kaufer","year":"2000","unstructured":"Kaufer D, Cummings J, Ketchel P et al (2000) Validation of the NPI-Q, a Brief clinical Form of the Neuropsychiatric Inventory. J Neuropsychiatry Cli Neurosci 12:233\u2013239","journal-title":"J Neuropsychiatry Cli Neurosci"},{"key":"1229_CR46","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3233\/JAD-141449","volume":"43","author":"E Salvadori","year":"2015","unstructured":"Salvadori E, Poggesi A, Pracucci G, Inzitari D, Pantoni L, VMCI-Tuscany Study Group (2015) Development and psychometric properties of a neuropsychological battery for mild cognitive impairment with small vessel disease: the VMCI-Tuscany Study. J Alzheimers Dis 43:1313\u20131323","journal-title":"J Alzheimers Dis"},{"key":"1229_CR47","unstructured":"SAS Institute Inc (2015) Base SAS 9.4 procedures guide, 5th edn. SAS Institute Inc, Cary. \nhttp:\/\/support.sas.com"},{"key":"1229_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/608013","author":"A Poggesi","year":"2012","unstructured":"Poggesi A, Salvadori E, Pantoni L et al (2012) Risk and determinants of dementia in patients with mild cognitive impairment and brain subcortical vascular changes: a study of clinical, neuroimaging, and biological markers. The VMCI-tuscany study: rationale, design, and methodology. Int J Alzheimers Dis. \nhttps:\/\/doi.org\/10.1155\/2012\/608013","journal-title":"Int J Alzheimers Dis"},{"key":"1229_CR49","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jclinepi.2007.02.006","volume":"60","author":"GF Borm","year":"2007","unstructured":"Borm GF, Fransen J, Lemmens WA (2007) A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol 60:1234\u20131238","journal-title":"J Clin Epidemiol"},{"key":"1229_CR50","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jalz.2015.02.010","volume":"12","author":"E Salvadori","year":"2016","unstructured":"Salvadori E, Poggesi A, Valenti R et al (2016) Operationalizing mild cognitive impairment criteria in small vessel disease: the VMCI-Tuscany Study. Alzheimers Dement 12:407\u2013418","journal-title":"Alzheimers Dement"},{"key":"1229_CR51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000487130","volume":"8","author":"E Salvadori","year":"2018","unstructured":"Salvadori E, Poggesi A, Pracucci G et al (2018) Application of the DSM-5 criteria for major neurocognitive disorder to vascular MCI patients. Dement Geriatr Cogn Dis Extra 8:104\u2013116","journal-title":"Dement Geriatr Cogn Dis Extra"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-019-01229-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40520-019-01229-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-019-01229-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T19:16:33Z","timestamp":1590693393000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40520-019-01229-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s40520-019-01229-z","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AP, FP, ES, ID, RV, GC, MS, LT, AM, and FF report no disclosures. LP: member of the editorial boards of Cerebrovascular Diseases, Acta Neurologica Scandinavica, Neurological Sciences and European Stroke Journal; and section editor (Vascular Cognitive Impairment) of Stroke.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study is carried in accordance with the 1964 Helsinki Declaration and its later amendments and with the ethical standards of the institutional ethics committee, and was approved by the ethics committee of the Careggi University Hospital, Florence, Italy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}